ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

IL-6 Receptor Blockade But Not IL-2 Treatment Contributes to Long-Term NHP Cardiac Allograft Survival in Transient Mixed Chimeras

K. Ahrens1, J. M. O1, W. Sommer2, J. Morrissette1, D. Becerra1, P. M. Patel1, T. Costa1, A. Dehnadi1, I. M. Hanekamp1, J. S. Allan3, G. Benichou1, J. C. Madsen4

1Center for Transplantation Sciences, Massachusetts General Hospital, Boston, MA, 2Department of Cardiothoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover, Germany, 3Center for Transplantation Sciences, Division of Thoracic Surgery, Massachusetts General Hospital, Boston, MA, 4Center for Transplantation Sciences, Division of Cardiac Surgery, Massachusetts General Hospital, Boston, MA

Meeting: 2020 American Transplant Congress

Abstract number: 630

Keywords: Bone marrow, Heart, Primates, Tolerance

Session Information

Session Name: Tolerance / Immune Deviation

Session Type: Oral Abstract Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:45pm

 Presentation Time: 4:27pm-4:39pm

Location: Virtual

*Purpose: Long-term tolerance of cardiac allografts has been achieved in non-human primates (NHPs) using a mixed chimerism protocol and by co-transplanting a kidney from the same heart and bone marrow donor. In contrast, heart alone recipients rejected in 150-180 days. T cell subset analyses showed greater expansion of regulatory T cells (Treg) in heart/kidney recipients compared to heart alone controls. To achieve tolerance of isolated heart allografts, we added IL-2 and/or anti-IL6R therapy to enhance host Treg activity.

*Methods: Cynomolgus heart alone transplant recipients underwent donor bone marrow transplantation with conditioning that included non-myeloablative total body irradiation, thymic irradiation, equine anti-thymocyte globulin, anti-CD154 mAb, and cyclosporine until post-operative day (POD) 28. Five animals in Group A received low dose IL-2 (1MIU/m2 SC from POD -6 to 5) and IL-6 receptor blockade with tocilizumab (10 mg/kg IV on POD 0, 7, 14, 21, 28, 56, 84, and 112). Seven recipients in Group B, received tocilizumab alone (10 mg/kg IV on POD 0, 7, 14, 21, 28, 56, and 84).

*Results: In Group A, 3/5 animals rejected their allografts at POD 127, 198, and 254 with evidence of acute cellular rejection (ACR), antibody mediated rejection (AMR), and donor specific antibodies (DSA). Two animals died on POD 7 and 11 from sepsis and pancytopenia, respectively. In Group B, 3/7 recipients are ongoing (POD 159 and 110) with one animal over 558 days with no evidence of ACR. 1/7 rejected at POD 169 with ACR3R, pAMR3, and DSA and 3/7 animals died on POD 5, 9, and 65 from a technical failure, sedation complication, and pancytopenia, respectively. Recipients in Group A exhibited an average 15-fold expansion in the percent CD25+FoxP3+ of CD3+CD4+ cells in the periphery compared to an average 3-fold expansion in Group B recipients.

*Conclusions: We have been able to achieve tolerance of an isolated heart allograft using IL-6 receptor blockade along with a regimen of reagents largely available for clinical use. The surprising deleterious effects of low dose IL-2 may be related to its ability to activate alloreactive T cells, despite augmenting Tregs.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Ahrens K, O JM, Sommer W, Morrissette J, Becerra D, Patel PM, Costa T, Dehnadi A, Hanekamp IM, Allan JS, Benichou G, Madsen JC. IL-6 Receptor Blockade But Not IL-2 Treatment Contributes to Long-Term NHP Cardiac Allograft Survival in Transient Mixed Chimeras [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/il-6-receptor-blockade-but-not-il-2-treatment-contributes-to-long-term-nhp-cardiac-allograft-survival-in-transient-mixed-chimeras/. Accessed May 29, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences